लोड हो रहा है...
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma A Review
IMPORTANCE: For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and several immune checkpoint blockers (ICBs) that hav...
में बचाया:
| में प्रकाशित: | JAMA Oncol |
|---|---|
| मुख्य लेखकों: | , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2021
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8265820/ https://ncbi.nlm.nih.gov/pubmed/33090190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3381 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|